1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Cipla Acquires Inzpera Healthsciences: A Strategic Bet on Pediatric & Wellness Growth

04 Dec 2025
Admin
News Article

Cipla Acquires Inzpera Healthsciences: A Strategic Bet on Pediatric & Wellness Growth

Cipla has announced a major expansion move, acquiring 100% of Inzpera Healthsciences for ₹110.65 crore. The deal strengthens Cipla’s footprint in pediatric and wellness therapies, two of the fastest-growing consumer health segments in India.

Why This Acquisition Matters?

Inzpera, founded in 2016, has built a strong reputation for pediatric and wellness-focused products. The company reported ₹26.75 crore revenue in the last fiscal year, reflecting consistent market traction in child-focused therapeutics.

By integrating Inzpera’s portfolio with Cipla’s scale and distribution power, the deal creates a foundation for accelerated growth across metro, Tier-II, and Tier-III markets.

What Cipla Gains?

A diverse pediatric product pipeline: Inzpera brings formulations designed specifically for children’s health—an area with rising demand.
Wellness-driven innovations: The portfolio complements Cipla’s push into everyday health and consumer wellness.
A stronger distribution engine: Cipla’s nationwide network ensures faster market penetration and broader accessibility.
Scalability & operational efficiency: Cipla’s manufacturing and supply-chain strengths will help expand Inzpera’s offerings at scale.

What This Means for the Market?

This acquisition signals Cipla’s intent to deepen its presence in categories beyond traditional prescription drugs. With Indian parents increasingly prioritizing preventive care, child nutrition, and respiratory wellness, a combined Cipla–Inzpera portfolio positions the company strategically for long-term consumer health leadership.